Stockholders' Equity (Details Narrative) - USD ($) |
Sep. 30, 2019 |
Mar. 31, 2020 |
Dec. 31, 2019 |
|---|---|---|---|
| Preferred stock, shares issued | |||
| Preferred stock, shares outstanding | |||
| Pledge Agreement with PoC [Member] | |||
| Clinical trial funding commitment | $ 1,800,000 | ||
| Reduced clinical trial funding commitment | $ 900,000 | ||
| Number of common stock, pledged | 56,640 | ||
| Warrants to purchase common stock, pledged | 56,640 |
| X | ||||||||||
- Definition Warrants to purchase common stock, pledged. No definition available.
|
| X | ||||||||||
- Definition Clinical Trial Funding commitment in reduction for subscription receivable. No definition available.
|
| X | ||||||||||
- Definition Reduced clinical trial funding commitment. No definition available.
|
| X | ||||||||||
- Definition Number of common stock, pledged. No definition available.
|
| X | ||||||||||
- Definition Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|